Indian Drugmakers Rattled by Trump’s 100% Levy on Generic Drugs

Indian pharmaceutical companies are feeling the heat due to President Trump's proposed 100% tariff on generic drugs, a move that has caused significant concern in the industry. This policy shift threatens to disrupt their lucrative business in the U.S., which is their largest export market. The potential financial impact and strategic recalibration this imposes could reshape their global trade dynamics and affect pricing and availability of essential medications. This development underscores the broader implications of international trade policies on global healthcare supply chains.